WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Abbott

AbbottAt Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

www.abbott.com

Abbott RSS Channel

Filters
List of articles in category Abbott
Title Published Date
Abbott Reports 16.1 Percent Sales Growth in Fourth Quarter 23 January 2008
The Magic Johnson Foundation and Abbott Expand Focus of 'Campaign to End Black AIDS' 30 November 2007
Abbott Partners With Operation Smile to Support 40 Medical Missions in 25 Countries 16 November 2007
One-Year Results from the Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 25 October 2007
Abbott Named to Science Magazine's List of Top Employers 25 October 2007
Abbott Reports 14.4 Percent Sales Growth in Third Quarter 18 October 2007
Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine 11 October 2007
Prix Galien USA Names HUMIRA Best Biotechnology Product 28 September 2007
Dow Jones Sustainability Index Again Recognizes Abbott 11 September 2007
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
  • End
Tahmeena

Business & Industry

  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed

Research & Development

  • Antidepressants used for chronic pain on the rise, but are they effective?
  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Abbott

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.